MX2012004833A - Analisis para detectar anticuerpos especificos a anticuerpos anti-ige terapeuticos y su uso en anafilaxis. - Google Patents

Analisis para detectar anticuerpos especificos a anticuerpos anti-ige terapeuticos y su uso en anafilaxis.

Info

Publication number
MX2012004833A
MX2012004833A MX2012004833A MX2012004833A MX2012004833A MX 2012004833 A MX2012004833 A MX 2012004833A MX 2012004833 A MX2012004833 A MX 2012004833A MX 2012004833 A MX2012004833 A MX 2012004833A MX 2012004833 A MX2012004833 A MX 2012004833A
Authority
MX
Mexico
Prior art keywords
anaphylaxis
therapeutic anti
assays
ige
antibodies
Prior art date
Application number
MX2012004833A
Other languages
English (en)
Other versions
MX344935B (es
Inventor
Henry B Lowman
Saloumeh Fischer
Dana L Baker
Gerald R Nakamura
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2012004833A publication Critical patent/MX2012004833A/es
Publication of MX344935B publication Critical patent/MX344935B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención prove métodos y reactivos útiles para detectar anticuerpos anti-fármaco de isotipo IgE para anticuerpos anti-IgE terapéuticos y métodos para determinar el riesgo de anafilaxis a la administración de un anticuerpo anti-IgE terapéutico.
MX2012004833A 2009-10-26 2010-10-26 Analisis para detectar anticuerpos especificos a anticuerpos anti-ige terapeuticos y su uso en anafilaxis. MX344935B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25505209P 2009-10-26 2009-10-26
PCT/US2010/054160 WO2011056606A1 (en) 2009-10-26 2010-10-26 Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis

Publications (2)

Publication Number Publication Date
MX2012004833A true MX2012004833A (es) 2012-07-04
MX344935B MX344935B (es) 2017-01-11

Family

ID=43970265

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004833A MX344935B (es) 2009-10-26 2010-10-26 Analisis para detectar anticuerpos especificos a anticuerpos anti-ige terapeuticos y su uso en anafilaxis.

Country Status (19)

Country Link
US (1) US9315583B2 (es)
EP (1) EP2494356B1 (es)
JP (1) JP6139885B2 (es)
KR (1) KR101832510B1 (es)
CN (1) CN102695956B (es)
AU (1) AU2010315470B2 (es)
BR (1) BR112012009846B8 (es)
CA (1) CA2778810C (es)
DK (1) DK2494356T3 (es)
HK (1) HK1175538A1 (es)
HU (1) HUE033492T2 (es)
IL (1) IL219337A (es)
MX (1) MX344935B (es)
MY (1) MY182750A (es)
NZ (1) NZ599600A (es)
RU (1) RU2642295C2 (es)
SI (1) SI2494356T1 (es)
WO (1) WO2011056606A1 (es)
ZA (1) ZA201202999B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062627A2 (en) 2008-10-27 2010-06-03 Genalyte Inc. Biosensors based on optical probing and sensing
WO2013066986A1 (en) * 2011-10-31 2013-05-10 Puget Sound Blood Genter Antibody response phenotyping
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
JP6571660B2 (ja) * 2013-12-20 2019-09-04 フアデイア・アー・ベー 抗体の分析
CA2967817C (en) * 2014-11-14 2022-03-15 Biomerica, Inc. Compositions, devices, and methods of ibs sensitivity testing
TWI691512B (zh) 2015-02-20 2020-04-21 日商橘生藥品工業股份有限公司 Ｆｃ融合高親和性ＩｇＥ受體α鏈
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
KR101957411B1 (ko) 2017-09-13 2019-03-12 (주)뷰티화장품 생약 추출물 함포 펙틴 마이크로캡슐을 포함하는 피부 개선용 화장료 조성물
JP7041272B2 (ja) * 2018-01-12 2022-03-23 ジーアイ・イノベイション・インコーポレイテッド プロバイオティクスおよびＩｇＥへの結合親和性を有するポリペプチドを含む組成物およびその使用
US20210231651A1 (en) * 2018-04-30 2021-07-29 Genalyte, Inc. Methods and compositions for point of care measurement of the bioavailability of therapeutic biologics
CN113474657A (zh) * 2019-02-21 2021-10-01 丁勤学 使用微粒去除非特异性结合信号的方法
CA3145382A1 (en) * 2019-07-08 2021-01-14 Gi Innovation, Inc. Polypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of ige fc receptor, and pharmaceutical composition comprising same
CN112285351A (zh) * 2019-07-22 2021-01-29 上海益诺思生物技术股份有限公司 一种抗IgE单抗的ELISA检测方法
CN110358738B (zh) * 2019-08-22 2021-08-13 中国食品药品检定研究院 一种稳定测定抗IgE抗体药物生物学活性的方法
WO2022078466A1 (en) * 2020-10-14 2022-04-21 I-Mab Biopharma Co., Ltd. Methods for mitigating interference by therapeutic anti-cd47 antibodies in pre-transfusion assays
JP7062803B1 (ja) * 2021-03-31 2022-05-06 積水メディカル株式会社 抗薬物抗体測定方法
CN114047343B (zh) * 2022-01-13 2022-05-31 美迪西普亚医药科技(上海)有限公司 双耐受型抗IgE单抗药物的免疫原性分析试剂盒及其使用方法和应用
CN116699147A (zh) * 2023-08-04 2023-09-05 军科正源（北京）药物研究有限责任公司 检测总IgE含量的方法以及相关试剂盒

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (es) * 1967-05-23 1971-08-02 Pharmacia Ab
US3720760A (en) * 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
GB1319315A (en) * 1969-06-19 1973-06-06 Citizen Watch Co Ltd Calendar timepiece
US3691016A (en) * 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) * 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (en) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) * 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) * 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) * 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) * 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4459359A (en) * 1981-11-19 1984-07-10 New York Blood Center, Inc. Sensitive immunoassays of antigens or antibodies sequestered within immune complexes
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4683136A (en) * 1985-03-06 1987-07-28 Scripps Clinic And Research Foundation Proteinaceous antigens with conformation-independent and conformation-dependent determinants
US4737456A (en) * 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) * 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992017207A1 (en) 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
JPH0772150A (ja) * 1993-09-02 1995-03-17 Tonen Corp ＩｇＥの測定方法
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
KR100942002B1 (ko) 1996-12-03 2010-02-12 암젠 프레몬트 인코포레이티드 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린 유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된 항체
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
EP1021723B1 (en) * 1997-09-22 2008-12-10 Novartis Vaccines and Diagnostics, Inc. Buffers for stabilizing hcv antigens
AU1344102A (en) * 2000-10-12 2002-04-22 Genentech Inc Reduced-viscosity concentrated protein formulations
EP1527099A2 (en) * 2002-08-01 2005-05-04 Northwestern University Mutants of ige proteins and uses thereof
CN102993306B (zh) 2003-02-01 2015-01-28 唐纳士公司 高亲和力抗人类IgE抗体
ZA200507757B (en) * 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
ES2340767T5 (es) * 2004-07-01 2013-11-13 Biomay Ag Alérgenos de ácaros del polvo doméstico
AU2005282720B2 (en) * 2004-09-02 2011-08-04 Genentech, Inc. Anti-FC-gamma RIIB receptor antibody and uses therefor
ATE439598T1 (de) * 2005-10-17 2009-08-15 Pls Design Gmbh Chimäre zwischen einer alpha-kette eines humanen ige rezeptor und konstanten immunoglobulin- domänen von vögeln zur determination von serum ige.
US20070184501A1 (en) * 2006-02-07 2007-08-09 Beckman Coulter, Inc. Blocker reagent for reduction of heterophile interferences
WO2008028068A2 (en) * 2006-08-30 2008-03-06 Genentech, Inc. NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES

Also Published As

Publication number Publication date
IL219337A (en) 2017-06-29
WO2011056606A8 (en) 2012-05-18
MX344935B (es) 2017-01-11
ZA201202999B (en) 2013-06-26
HUE033492T2 (en) 2017-12-28
MY182750A (en) 2021-02-05
NZ599600A (en) 2015-04-24
DK2494356T3 (en) 2017-05-15
CA2778810C (en) 2018-09-04
BR112012009846A2 (pt) 2017-02-21
US9315583B2 (en) 2016-04-19
JP6139885B2 (ja) 2017-05-31
US20110183363A1 (en) 2011-07-28
AU2010315470A1 (en) 2012-05-24
RU2012121559A (ru) 2013-12-10
EP2494356A4 (en) 2013-07-03
IL219337A0 (en) 2012-06-28
KR101832510B1 (ko) 2018-02-26
BR112012009846B8 (pt) 2021-05-25
WO2011056606A1 (en) 2011-05-12
KR20120116400A (ko) 2012-10-22
RU2642295C2 (ru) 2018-01-24
HK1175538A1 (zh) 2013-07-05
CN102695956A (zh) 2012-09-26
JP2013508740A (ja) 2013-03-07
EP2494356A1 (en) 2012-09-05
CN102695956B (zh) 2015-12-09
AU2010315470B2 (en) 2016-05-05
CA2778810A1 (en) 2011-05-12
BR112012009846B1 (pt) 2021-04-20
EP2494356B1 (en) 2017-03-15
SI2494356T1 (sl) 2017-07-31

Similar Documents

Publication Publication Date Title
MX344935B (es) Analisis para detectar anticuerpos especificos a anticuerpos anti-ige terapeuticos y su uso en anafilaxis.
AU2018200278B2 (en) Antibodies to aripiprazole and use thereof
IL208517A (en) Antibody-specific monoclonal antibodies associated with humanized CD70 and methods for identifying CD70 expression
EP3933406A3 (en) Antibodies to risperidone and use thereof
WO2010065568A3 (en) METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
MX357231B (es) Polipeptidos de anticuerpos que antagonizan el ligando cd40 (cd40l).
EA201290413A1 (ru) МУТИРОВАННЫЕ Fc АНТИТЕЛ С УСТРАНЕННЫМИ ЭФФЕКТОРНЫМИ ФУНКЦИЯМИ
UA111340C2 (uk) Антитіло, яке специфічно зв'язується з tnf-альфа людини
BRPI0921805A2 (pt) anticorpos que especificamente bloqueiam a atividade biológica de um antígeno de tumor
NZ602220A (en) Antibodies with ph dependent antigen binding
NZ630433A (en) Antibodies and uses thereof to detect folate receptor 1
WO2014031668A3 (en) Antibodies to quetiapine and use thereof
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
WO2014031662A3 (en) Antibodies to olanzapine and use thereof
EP2322562A4 (en) MONOCLONAL ANTIBODY AND IMMUNASSAY WITH IT
WO2010078950A3 (en) Antigens associated with endometriosis, psoriatic arthritis and psoriasis
BRPI1005176A2 (pt) ensaio de insulina, reagente de ensaio de insulina, anticorpo monoclonal, e, método de triar anticorpos monoclonais.
ATE500503T1 (de) Cd86- und cd80-rezeptorkonkurrenztests
EP2536817A4 (en) IMMUNOASSAY DEVICES FOR THE DETECTION OF ANTIBODIES AND ANTIGENES
CL2013000411A1 (es) Ensayo de union a blanco in vitro de funcion dual no basado en celulas para la deteccion de anticuerpos blancos y anticuerpos neutralizantes contra dichos anticuerpos blancos.
BR112013030008A2 (pt) imunoensaio de clozapina
MX2007013108A (es) Reactivos que enlazan ccx-ckr2.
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3
GB0611708D0 (en) Novel antibodies against prion protein and uses thereof
WO2010053772A3 (en) Disease-associated antigens and methods of use thereof

Legal Events

Date Code Title Description
FG Grant or registration